Trials / Completed
CompletedNCT01952132
Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects
Phase 2 Randomized, Double-blind, Placebo-controlled, Sequential Dose Escalation Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Omeros Corporation · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in psychiatrically stable schizophrenia patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OMS643762 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2013-09-27
- Last updated
- 2018-10-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01952132. Inclusion in this directory is not an endorsement.